Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.
Summary
This bill amends New York’s Public Health Law to add five conditions to the state newborn screening panel: late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2), mucopolysaccharidosis type IVA (MPS IVA), mucopolysaccharidosis type VI (MPS VI), mucopolysaccharidosis type VII (MPS VII), and Fabry disease. It directs the Commissioner of Health to ensure that tests for these diseases are made available within 12 months after the new screening requirements take effect.
In practical terms, the bill expands the state’s mandatory newborn screening program so that infants born in New York would be screened for these rare, serious genetic and metabolic disorders. The measure takes effect immediately and would require the public health system and any associated testing infrastructure to incorporate the new conditions into routine newborn screening operations on the statutory timeline specified in the bill.
Impact
The bill would amend section 2500-a of the Public Health Law by adding five new conditions to the list of diseases for which newborn screening must be offered in New York. It also creates a new subdivision requiring the commissioner to make testing available for those conditions within 12 months of the effective date, thereby imposing an implementation deadline on the state health system and screening laboratories. The primary affected parties are newborns and their families, the Department of Health, and clinical laboratories responsible for screening and follow-up testing.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the measure appears to be a straightforward public health expansion with an implied supportive policy rationale: earlier detection of rare diseases in newborns. The bill’s structure suggests a technical, health-focused proposal rather than a controversial one, and there is no available evidence in the provided materials of organized opposition or divided sentiment. The immediate effective date and mandated testing timeline indicate urgency and a preventive health orientation.
Contention
No committee transcripts or voting history were provided, so there are no recorded points of contention in the supplied materials. Potential areas of practical concern, if raised, would likely involve implementation costs, laboratory readiness, test availability, and the capacity of the newborn screening program to add multiple rare-disease assays within the required 12-month period. However, those issues are not documented in the bill context provided.
Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.